GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » Property, Plant and Equipment

Vir Biotechnology (Vir Biotechnology) Property, Plant and Equipment : $162.82 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology Property, Plant and Equipment?

Vir Biotechnology's quarterly net PPE declined from Sep. 2023 ($171.93 Mil) to Dec. 2023 ($167.20 Mil) and declined from Dec. 2023 ($167.20 Mil) to Mar. 2024 ($162.82 Mil).

Vir Biotechnology's annual net PPE increased from Dec. 2021 ($130.05 Mil) to Dec. 2022 ($188.17 Mil) but then declined from Dec. 2022 ($188.17 Mil) to Dec. 2023 ($167.20 Mil).


Vir Biotechnology Property, Plant and Equipment Historical Data

The historical data trend for Vir Biotechnology's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology Property, Plant and Equipment Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
Get a 7-Day Free Trial 16.31 79.89 130.05 188.17 167.20

Vir Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 185.26 179.06 171.93 167.20 162.82

Vir Biotechnology Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Vir Biotechnology  (NAS:VIR) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Vir Biotechnology Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology (Vir Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Executives
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang officer: Chief Medical Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De officer: Chief Executive Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee officer: Chief Financial Officer 7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos director, officer: President and CEO C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn officer: CFO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin officer: EVP, Research & CSO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano director C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001

Vir Biotechnology (Vir Biotechnology) Headlines

From GuruFocus